Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

NEXT STORY
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
PREV STORY
Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

2016 Results: Significant Milestones, First Profit, More Growth to Come

Two global license and license option agreements signed with Janssen Biotech in July and ...

author_avatar
NASDAQ Market News

OpGen Provides Update on Shareholder Proxy Voting in Relation to the Business Combination with Curetis

author_avatar
NASDAQ Market News

Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology

MENLO PARK, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused ...

author_avatar
NASDAQ Market News